Evolution of Lesions on CT Scan During and After Neutropenia
| Patient . | Organs* Involved . | First Cycle† . | Second Cycle† . | Long-Termρ . | ||
|---|---|---|---|---|---|---|
| . | . | During Neutropenia‡ . | After Neutropenia‡ . | During Neutropenia‡ . | After Neutropenia‡ . | . |
| A | Liver, spleen | Disappearance (6 d) | Reappearance (46 d) | Decrease (15 d) | Increase (35 d) | Disappearance (230 d, 94 d) |
| B | Liver | Decrease (16 d) | Increase (31 d) | NA | NA | Disappearance (129 d) |
| C | Spleen, liver | Disappearance (9 d) | Reappearance (7 d) | NA | NA | Disappearance (152 d) |
| D | Liver | Decrease (11 d) | Increase (18 d) | Decrease (12 d) | Unchanged (21 d) | Disappearance (107 d) |
| E | Liver, spleen | Decrease (16 d) | Increase (20 d) | Unchanged (11 d) | Decrease (51 d) | Disappearance (135 d, 17 d) |
| Patient . | Organs* Involved . | First Cycle† . | Second Cycle† . | Long-Termρ . | ||
|---|---|---|---|---|---|---|
| . | . | During Neutropenia‡ . | After Neutropenia‡ . | During Neutropenia‡ . | After Neutropenia‡ . | . |
| A | Liver, spleen | Disappearance (6 d) | Reappearance (46 d) | Decrease (15 d) | Increase (35 d) | Disappearance (230 d, 94 d) |
| B | Liver | Decrease (16 d) | Increase (31 d) | NA | NA | Disappearance (129 d) |
| C | Spleen, liver | Disappearance (9 d) | Reappearance (7 d) | NA | NA | Disappearance (152 d) |
| D | Liver | Decrease (11 d) | Increase (18 d) | Decrease (12 d) | Unchanged (21 d) | Disappearance (107 d) |
| E | Liver, spleen | Decrease (16 d) | Increase (20 d) | Unchanged (11 d) | Decrease (51 d) | Disappearance (135 d, 17 d) |
Abbreviation: NA, not applicable.
The organ with more visible lesions is listed first.
“First cycle” and “second cycle” refer to the first cycle and the second cycle after the diagnosis of hepatic candidiasis. The total number of chemotherapy cycles with prolonged neutropenia before and after the diagnosis of hepatic candidiasis is listed in Table 1.
“During neutropenia” refers to lesions on a CT scan performed while the patient was neutropenic. The number of days of severe neutropenia (<500/μL) passed at the time the scan was performed is listed in parentheses. “After neutropenia” refers to lesions on a CT scan performed after recovery from severe neutropenia. The number of days from recovery of severe neutropenia (>500/μL) until the scan was performed is listed in parentheses.
ρ “Long-term” refers to the first CT scan on which all lesions had disappeared. The number of days from recovery of the last period of neutropenia until the scan was performed is listed in parentheses. Patients A and E underwent alloBMT 6 and 3 months after their last chemotherapy. For them, both the duration from the last chemotherapy-induced, as well as from alloBMT-induced neutropenia, is listed. In both patients, hepatic lesions were visible at admission for alloBMT and disappeared later. No CT scans were performed during alloBMT.